News for Affimed N.V. (AFMD)

After disclosing revised clinical results for its AFM24/atezolizumab combination treatment in non-small cell lung cancer, Affimed N.V. (AFMD, Financials) shares

Affimed (AFMD) stock plunged 23% after the company reported updated data from a clinical trial of AFM24/atezolizumab in the treatment of non-small cell lung cancer. Read more here.

New York-based Syntec Optics Holdings, Inc. (OPTX) is up over 167 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Affimed N.V. (AFMD), Tuesday announced the updated clinical results from the ongoing AFM24-102 trial, evaluating the AFM24/atezolizumab combination therapy in heavily pretreated non-small cell lung cancer or NSCLC patients.

AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest d

MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. ( AFMD) (”œAffimed”, or the ”œCompany”), a clinical-stage immuno-oncology company comm

**media[486945]**

The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R

Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed s

**media[484151]**

Operator: Good day, everyone. And welcome to Affimed’s Third Quarter 2024 Earnings and Corporate Update Call. At this time, all participants are in a listen-only mode.

Essential Pharma Announces the Appointment of Dr Liz Holmes as Chief Medical Officer

In the first full week of September, the market is expected to see a limited number of earnings reports due to a holiday-shortened schedule. However, several hi

The increase in the prevalence of Non-Small Cell Lung Cancer (NSCLC) drives market growth by boosting demand for innovative treatments, and personalized...

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.30%

Loading... Loading... Shares of Science Applications International Corporation SAIC declined 11% to $119.91 following first-quarter results. SAIC reported a 9...

Roivant Sciences Ltd., with its differentiated drug development pipeline and strategic investments, shows strong upside prospects in 2024. Click for my ROIV update.

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

“Natural Killer (NK) Cell Therapeutics Market” from 2024-2034 with covered segments (Natural Killer (NK) Cell Therapeutics Market, By Type (NK Cell...